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Abstract
Aims: Atrial natriuretic petide (ANP), brain natriuretic peptide (BNP) and endothelin-1 (ET-1) may reflect the severity of right
ventricular dysfunction (RVD) in patients with pulmonary embolism (PE). The exact nature and source of BNP, ANP and ET-1
expression and secretion following PE has not previously been studied.
Methods and Results: Polystyrene microparticles were injected to induce PE in rats. Gene expression of BNP, ANP and ET-1
were determined in the 4 cardiac chambers by quantitative real time polymerase chain reaction (QPCR). Plasma levels of
ANP, BNP, ET-1 and cardiac troponin I (TNI) were measured in plasma. PE dose-dependently increased gene expression of
ANP and BNP in the right ventricle (RV) and increased gene expression of ANP in the right atrium (RA). In contrast PE dose-
dependently decreased BNP gene expression in both the left ventricle (LV) and the left atrium (LA). Plasma levels of BNP, TNI
and ET-1 levels dose-dependently increased with the degree of PE.
Conclusion: We found a close correlation between PE degree and gene-expression of ANP, and BNP in the cardiac chambers
with a selective increase in the right chambers of the heart. The present data supports the idea of natriuretic peptides as
valuable biomarkers of RVD in PE.
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Introduction
Cardiovascular homeostasis and function results from complex
interactions of various regulatory factors. Among these are the
cardiac natriuretic peptides (atrial natriuretic petide (ANP) and
brain natriuretic peptide (BNP) as well as endothelin-1 (ET-1). The
cardiac gene expression and plasma level of ANPand BNP and ET-
1 hasbeensubject of intenseinvestigationconcerning their potential
role and secretion in response to acute pulmonary embolism (PE).
The natriuretic peptides are biologically active substances capable
of inducing diuresis, natriuresis and reducing systemic blood
pressure. Plasma concentration of the hormones are augmented
in patients with chronic heart failure and predicts left ventricular
(LV) ejection faction (EF), mortality and morbidity in these
patients[1]. BNP level is also increased in valvular diseases, chronic
pulmonary hypertension and chronic right ventricular dysfunction
(RVD)[2]. BNP in particular originates from the ventricles of the
heart and is released in response to increased filling pressure[3].
ANP is released by distension, primarily from atrial tissue in healthy
subjects. ET-1 is released from endothelial cells in the pulmonary
circulation. ET-1 plasma levels correlate with the pulmonary
pressure, and abnormalities in the circulating levels of ET-1 have
been reported in an experimental PE model[4].
Also in patients ANP, BNP and ET-1 are released in response to
volume expansion and pressure overload and may identify
RVD[5] and have been shown to correlate with the severity of
RVD in PE patients[6]. Patients with RVD after PE have a worse
prognosis and may have increased mortality compared with those
who have a normal RV function[7] and these biomarkers may
therefore help to stratify these patients[8].
Previous studies have shown that the gene expression of BNP,
ANP and ET-1 is induced both in the RV and LV in a chronic
model of RVD[9,10]. But no one has so far showed the origin and
extent of gene expression of these hormones in response to acute
PE.
Our hypothesis was therefore that the gene expression of ANP,
ET-1 and BNP was upregulated in the RV during PE and the
hormone plasma concentration and gene expression was correlat-
ed to the extent of PE.
Therefore, the aim of our study was to quantitatively establish
the gene expression profiles of BNP, ANP and ET-1 in all 4
chambers of the heart in rats during various degrees of PE. To do
so, we used quantitative real-time polymerase chain reaction
(QPCR) to measure the levels of the gene expression during
various degrees of experimental PE in a rat model of PE. In
addition, the associations between the gene expression profiles of
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to evaluate the association between the soluble biomarker and
local gene expression levels.
Materials and Methods
Animal care and all experimental procedures were performed
under the approval of the Danish Animal Welfare Council (2006/
561-1124). Experiments were performed using male Sprague-
Dawley rats (Charles River, Sulzfeld, Germany) weighing between
328–400 g. The rats were housed 2 animals per cage, with a
12:12-h light-dark cycle and received standard rat chow and water
ad libitum throughout the course of experiments.
Pulmonary embolism model
Polystyrene microspheres were used to create pulmonary
embolism as previously described[11]. Microspheres (2561 mm;
Duke Scientific catalogue no. 7525, Fremont, Ca, USA) were
sterilized with 70% ethanol, washed with sterile 0.01% Tween 20,
and resuspended in 0.01% sterile Tween 20 to produce a 10%
suspension (10.39 million beads/mL). All animals were anesthe-
tized with 3% sevoflurane (Abbott Scandinavia AB, Solna,
Sweden) mixed with 35% O2 in N2 by breathing. The rats were
randomly assigned to 4 groups. Microspheres were injected via a
tail vein to produce mild (0.87 million beads/100 g body weight,
referred to as PE 0.87), moderate (1.30 million beads/100 g body
weight, referred to as PE 1.30) and severe PE (1.95 million beads/
100 g body weight, referred to as PE 1.95). Sham animals received
vehicle (0.01% Tween 20, 0.15 mL/100 g body weight). After
16 hours of treatment, all animals were anesthetized with 3%
sevoflurane (Abbott Scandinavia AB, Solna, Sweden) mixed with
35% O2 in N2 by breathing and subsequently decapitated. Blood
was collected in EDTA containers with 500 mL Trasylol,
10.000 KIE/mL (Bayer HealthCare, Leverkusen, Germany),
centrifuged at 2,0006g for 15 min, and plasma was transferred
to a fresh tube and stored at 280uC until analyzed.
Tissue dissection, RNA extraction and Reverse
Transcription
The heart tissue was removed, dissected into RV, LV, right
atrium (RA), left atrium (LA) and interventricular septum (IVS)
and weighed and hereafter placed in RNAlaterH (Ambion (Europe)
Limited, Cambridgeshire, UK), and stored at 4uC. The following
day the RNAlaterH was removed and the samples were stored at
280uC for later use.
Total RNA (20–30 mg) was isolated using NucleoSpin RNA II
Kit (Macherey-Nagel, Du ¨ren, Germany). The total RNA
concentration was measured on a Bioanalyzer 2100 (Agilent
Technologies, Waldbronn, Germany); using RNA 6000 Nano kit
(Agilent, Technologies, Waldbronn, Germany). Total RNA was
reverse transcribed using AffinityScript QPCR cDNA Synthesis
Kit (Stratagene, La Jolla, CA, USA). The cDNA was immediately
cooled down and stored at 220uC.
Quantitative real-time PCR
The primers and LNA (Locked Nucleic Acid) fluorescent probes
for the three genes of interest BNP (NM_031545), ET-1
(NM_012548), ANP (NM_012612) and the housekeeping gene
TBP ((TATAA-box Binding Protein, NM_001004198) were
designed using the software Beacon Designer (version 6.0, Premier
BioSoft, Palo Alto, CA, USA). The primer and probe sequences
were purchased from Sigma-Genesis (Sigma-Aldrich, St-Louis,
MO, USA). The primers and probes are shown in Table 1. Each
PCR reaction was optimized regarding forward primer (FP),
reverse primer (RP) and probe concentrations (final): BNP FP/RP
300/600 nM, probe 300 nM; ANP FP/RP 300/300 nM, probe
200 nM; ET-1 FP/RP 300/600 nM, probe 300 nM and TBP
FP/RP 300/300 nM, probe 100 nM.
The gene quantification was performed on an Mx3000PH
QPCR instrument (Stratagene, La Jolla, CA, USA). The three
genes of interest were quantified in duplex assays with TBP. All
samples were run in triplicates in a total volume of 25 ml using 1 ml
cDNA. Brilliant QPCR Core Reagent Kit (Stratagene) was used.
Optimization of the assays resulted in a 50% increase of both
dNTP and Taq DNA Polymerase and an MgCl2 concentration of
5.5 mM. The thermal profile used was: 1 cycle at 95uC for 10 min
(denaturizing), 45 cycles at 95uC for 30 sec and 60uC for 1 min
(annealing/elongation).
The optimal housekeeping gene for this study was selected from
a panel of 8 common rat endogenous genes (primer-sets from
PrimerDesign, Southampton, UK). All genes were tested in tissues
from rat hearts representing the 4 groups: 1 treated and 3
untreated groups (n=10 in each group). By using NormFinder
algorithm[12] the overall most stable housekeeping gene was
found to be TBP.
Relative quantification of the genes was calculated using the
comparative method (2
2DDCt)[13]. Beside TBP as a housekeeping
gene, we also included a calibrator group represented by untreated
animals. The efficiency of the PCR (E) was calculated from 5-fold
dilution curves for each gene in the PCR reaction. By replacing 2
with (E+1) in the expression 2
2DDCt, we thereby compensated for
variations in the PCR reactions.
To estimate the relative expression of gene of interest in the
different cardiac chambers RV was used as calibrator and
compared to LV, RA and LA.
Blood sample analysis
TNI and BNP was measured by an automated two-site
sandwich immunoassay technique using chemiluminescence
(Siemens, ADVIA Centaur, Leverkusen, Germany).
ANP was measured using an ELISA kit and the lower detection
limit for NT-pro-ANP (1–98) was 0.05 nmol/L and the intra- and
interobserver CV were 2% and 4%, respectively.
The lower detection limit for NT-pro-ANP (1–98) was
0.05 nmol/L and the intra- and interassay coefficients of variation
were 2% and 4%, respectively.
The sensitivity of the Cardiac Troponon I (TNI) assay was
0.015 ng/ml and an interassay coefficient of variation was 10%.
BNP was analyzed using a kit for rats (BNP-45 EIA kit, Phoenix
Pharmaceuticals Ca, USA). The sensitivity of the assay was
0.3 ng/ml and the intra- and interassay coefficients of variation
were ,5% and ,14%, respectively.
ET-1 was measured with enzyme-linked immunosorbent assay
(ELISA) kits (Biomedica, Eching, Germany). The assay measures
the physiologically active ET peptide (1–21). Lower detection limit
was 0.02 fmol/ml and the intra- and interassay coefficients of
variation were 4% and 6%, respectively.
Statistical analysis
A one-sample Kolmogorov-Smirnov procedure was performed
on all variables to test the assumption of normal distribution. The
hormone values were not found to be normal distributed and
accordingly log10 transformation was performed leading to normal
distribution. Gene expression data are presented as mean 6 SEM
relative to the control for each of the 4 chambers to show the effect
of PE. For comparison of relative gene expression in the 4
chambers, RV was used as reference. Comparisons between
expressions in chambers were made by paired t-test followed by
Natriuretic Peptides in PE
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considered significant. All statistical analyses were performed using
SPSS 15.0 (Chicago, IL, USA).
Results
Weights of the cardiac chambers and rats are presented in
table 2. There were no significant differences between the groups
of rats.
PE induced gene expression
BNP (figure 1). PE dose-dependently increased BNP gene
expression in the RV (2–6 fold; p,0.05-0.001). In contrast PE
dose-dependently decreased BNP gene expression in both the LV
(0.6-0.5 fold, p,0.001) and the LA (0.8-0.3, p,0.01-0.001). No
major changes were seen in the RA.
ANP (Figure 2). PE dose-dependently increased gene-
expression of ANP in the RV 8–9 fold (p,0.05) and in the RA
1.5 fold (p,0.001) compared to the control group. There was an
increase of ANP gene expression in LV in the PE 1.30 group
(p,0.05). No major changes were seen in the LA.
ET-1. No systematic changes were seen in ET-1 gene
expression in the RA, LA, LV and RV during PE (data not
shown).
Relative gene-expression levels in the cardiac chambers
BNP. In the control group BNP gene expression was 18 fold
higher in the RA and 6–7 fold higher in LV and LA compared to
RV expression (p,0.001).
In the PE 0.87 group BNP gene expression in RA was 9 fold
higher compared to the RV, LV and LA group (p,0.001).
In the PE 1.30 group BNP gene expression was 3.5 fold higher
(p,0.01) in the RA compared to LA and RV.
In PE 1.95 group the RA BNP gene expression was only 1.5 fold
higher compared to RV.
ANP. ANP was predominately expressed in the LA and the
RA in both the control and the PE treated groups compared to the
RV (300–1200 fold; p,0.001). The ANP gene-expression in the
atria compared to the ventricles was decreased as the degree of PE
increased.
ET-1. ET-1 mRNA were primarily expressed in the LA (4
fold), LV (2 fold) and RA (4.5 fold) in the control group compared
to the gene expression in the RV (p,0.001). This did not change
during PE p,0.001-0.01).
Plasma levels of pro-ANP, TN, ET-1 and BNP
Plasma levels pro-ANP, TNI, ET-1 and BNP are shown in
Figure 3.
Plasma BNP level (panel A) showed a significant increase from
control group to PE 1.30 and a decrease from PE 1.30 to 1.95.
There were no significant changes in the ANP plasma levels
(panel B).
Plasma ET-1 level (panel C) and TNI (panel D) significantly and
dose-dependently increased in the groups with PE.
Discussion
In the present study we measured gene expression of ANP, BNP
and ET-1 in the cardiac atria and ventricles in response to graded
acute PE in an animal model. To our knowledge, this has not
previously been done.
We found that gene expression of ANP and BNP were strongly
and dose dependently up-regulated in the RV during PE. Both
ANP and BNP gene expression reached maximum at PE 1.3 with
no further increase at PE 1.95. Therefore, it seems that gene
expression in RV was maximally stimulated in our model already
at PE 1.3. In addition, we found that the gene expression of BNP
was down-regulated in both left chambers in animals with
moderate and severe PE.
Comparing BNP gene expression in the control groups the
highest level of BNP expression was found in the RA followed by
LV. This was also shown in previous studies where the order of the
BNP mRNA concentration in the rat heart was RA.
LA.LV.RV[14] and with levels in the LV being approximately
three-fold lower than the atria in normal functioning hearts[15].
During PE the BNP gene expression increases in the RV and
Table 1. Primer and probe sequences.
Gene Forward primer, 59 -3 9 Reverse primer, 59-3 9 59-Flourophore LNA probe, 59-3 9 39- Quencher Amplicon length
ANP gaggagaagatgccggtag ctagagagggagctaagtg FAM cgcTtcAtcGgtCtgct BHQ-1 96 bp
BNP tgattctgctcctgcttttc gtggattgttctggagactg FAM taaTctGtcGccGctgg BHQ-1 91 bp
ET-1 tgattctcttgcctcttcttg tatggaatctcctggctctc FAM ccaCtcAggAatGgcac BHQ-1 110 bp
TBP tgcgttgatcttcagttctg cttgctgctagtctggattg HEX ctcTtgGctCctGtgc BHQ-1 75 bp
doi:10.1371/journal.pone.0011111.t001
Table 2. Rat weight and weight of the heart chambers.
BW (g) HW (g) LV (g) RV (g) IVS (g) HW/BW (%) RV/(LV+IVS) RV/BW (%)
Control (n=10) 354613 0.9460.06 0.4960.05 0.2260.03 0.2360.03 0.2660.01 0.3060.04 0.06160.01
PE 0.87 (n=10) 368615 0.9360.06 0.5160.04 0.2160.03 0.2160.03 0.2560.02 0.2960.04 0.05660.01
PE 1.30 (n=10) 357620 0.8760.10 0.4760.06 0.2160.05 0.1960.04 0.2460.03 0.3360.11 0.05960.02
PE 1.90 (n=10) 363611 0.8760.10 0.4560.07 0.2260.04 0.2060.03 0.2460.03 0.3360.07 0.06060.01
There were no significant differences between the rats. BW: body weight, HW: heart weight, LV: left ventricle, RV: right ventricle, RA: right atrium, LA: left atrium. IVS:
interventriclular septum. Mean6 SD.
doi:10.1371/journal.pone.0011111.t002
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relatively more important. In chronic left heart failure there is an
up-regulation of ventricular BNP secretion[16]and the LV
becomes the dominant chamber for peptide secretion[17]. Taking
the weight of the ventricles into account, 70% of all cardiac plasma
BNP derives from the ventricles under normal conditions and up
to 88% under pathophysiological conditions[18,19]. Plasma
hormone levels of BNP were dose-dependently increased in the
RV in the PE model. This also supports the idea that RV is the
dominant chamber in the secretion of BNP in PE. The model
showed that the cardiac gene responses seem to be maximal with
the PE 1.3 dose of microspheres, without further increase in the
most severe group of PE 1.95. In contrast with circulating BNP,
the ET-1 levels continued to increase in the PE 1.95 group beyond
those observed in the PE 1.30 group. So, this decrease in the
circulating BNP levels was not due to limited progression in
severity of the model. We speculate whether BNP was released and
peaked at an earlier time point in the severe group and with
depleted stores and gene expression already at maximum this
would lead to the observed circulating BNP level.
In the control group and during PE we found that the ANP
gene expression was expressed higher in the atria than in the
ventricles. Based on gene expression and chamber weights, our
data indicate that atria are the major source of ANP in the control
rats and during PE.
Our results show that ANP is mainly expressed in the atria and
is up-regulated on the right side of the heart in rats with PE. It has
previous been shown that ANP mRNA in the RV was increased in
an animal model of chronic pulmonary hypertension with RV
hypertrophy[20]. The present study is to the best of our knowledge
the first that uses QPCR on atrial tissue in an animal model of
acute PE. Previous studies on tissue specific expression of the ANP
gene have shown high-level expression in the RA and virtually
undetectable amounts of ANP mRNA and peptides in the LV of
healthy adult mammals[18] which was also confirmed in our
study. Over 90% of ANP released from the normal adult heart
originates from the atria[21]. ANP hormone level was unaffected
during PE. ANP is stored in atrial secretory granules and stretch
enhances the secretion. The depletable nature of this pool together
with low weight of the atria might explain the lack of release of
ANP during PE[22].
PE did not systematically affect gene expression of ET-1. ET-1
in the heart was expressed higher in the atria than in the ventricles.
Plasma hormone levels were dose-dependently increased in ET-1
in the PE model. There was no association between the level of
ET-1 in plasma and gene expression in the cardiac chambers,
probably because ET-1 is mainly synthesized and secreted from
the pulmonary endothelial cells rather than from the heart[23].
TNI plasma level was dose-dependently increased in the PE
model. TNI is released upon myocardial damage and it has been
speculated whether TNI plasma level could be used as a
prognostic index in patients with PE[24].
Injection of polystyrene microparticles has been a model for
experimental PE producing vascular occlusion with physiological
alterations similar to PE as observed in humans and causing RVD.
The method allows accurate grading of the vascular occlusion. It has
previously been demonstrated that the induction of PE 1.95 with this
dose of polystyrene microparticles produced a peak reduction in
mean arterial blood pressure (MAP) of approximately 25% from
basal measurements followed by partial recovery of arterial blood
pressure to ,10% below basal level. This dose also causes the in vivo
RV systolic blood pressure to increase from 30 mmHg at baseline to
55 mmHg measured 30 min after embolization, suggesting ,75%
pulmonary vascular occlusion[11,25].
PE increases pulmonary vascular resistance and RV afterload
by obstructing the pulmonary arteries. With elevated RV
Figure 2. ANP gene expression in the cardiac chambers. Sample
sizes were 10 rats in each group. Error bars indicate SEM. RV: right
ventricle, RA: right atrium, LV: left ventricle, LA: left atrium. TBP: TATA-
box binding protein. *P,0.05; **p,0.01; ***p,0.001 compared to the
control group.
doi:10.1371/journal.pone.0011111.g002
Figure 1. BNP gene expression in the cardiac chambers. Sample
sizes were 10 rats in each group. Error bars indicate SEM. RV: right
ventricle, RA: right atrium, LV: left ventricle, LA: left atrium. TBP: TATA-
box binding protein. *P,0.05; **p,0.01; ***p,0.001 compared to the
control group.
doi:10.1371/journal.pone.0011111.g001
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concurrent pericardial constraint, reduces LV preload through
interventricular interdependence and leads to impairment of the
systemic and pulmonary circulation[26]. The increased gene
expression of BNP likely reflects the acute hemodynamically
significant right heart strain with contractile dysfunction and
decreased cardiac output (CO) due to the PE. The decreased gene
expression of BNP in the LV is probably due to a likely decrease in
left sided pressure of the heart.
It is well known that myocardial wall stress is a stimulus for
synthesis and secretion of BNP in acute or chronic LV
dysfunction[27]. However there is accumulating evidence that
plasma concentration of BNP is associated with PE especially
when resulting in RVD. In addition increased plasma level of BNP
is a significant predictor of all cause and short term mortality, also
in normotensive patients and may be used for risk stratification in
PE patients[28]. With this study we have shown that there exists
an association between the severity of pulmonary occlusion and
thereby RVD in PE and the level of BNP gene expression.
Most studies investigating the neurohormonal activation in PE
have focused on BNP, however ANP is released in response to
chronic increase in pulmonary artery pressure in patients with
pulmonary hypertension[29] and few studies have concentrated on
the role of ANP in PE[30]. To our knowledge this is the first time
it is shown that ANP is up-regulated in the RV in PE, however the
secretion of ANP mainly comes from the atria which have lower
mass. This could explain why the plasma concentration of ANP
lacks the sensitivity of BNP plasma level in relation to PE.
In the present study we found a close correlation between PE
degree and gene-expression of ANP, and BNP in the cardiac
chambers with a selective increase in the right chambers of the
heart.
The present data supports the idea of natriuretic peptides as
sensitive biomarkers of RVD in PE.
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